. Eradication rate for a subgroup of patients with peptic ulcer disease in two groups were 83% and 74%, respectively (p=0.134 
INTRODUCTION
Helicobacter pylori (H. pylori) is a ubiquitous human gastric infection, with different worldwide prevalence noted (1) (2) (3) (4) (5) (6) , and it is a known cause of peptic ulcer disease (PUD) as well as gastric cancer (7) (8) (9) . Eradication in patients with H. pylori related PUD leads to a significant decrease in ulcer recurrence (10, 11) . The role of H. pylori in patients with non ulcer dyspepsia (NUD) is uncertain (12) . In geographic areas such as Iran that has a high incidence of gastric cancer, H. pylori eradication in first degree relatives of gastric cancer patients as well as mass eradication of other asymptomatic infected persons may be justifiable. Over the past decade, anti-H. pylori therapy has undergone a remarkable evolution. However, optimal treatment has not yet been established. Reported eradication rates in different trials are considerably variable, and depend on different drug combinations as well as the treatment duration. Furthermore, many drug combinations have suboptimal eradication rates. Antibiotic resistance due to wide spread injudicious drug use, racial differences, social and other factors related to drug compliance and also many other local variables may be causative factors. In contradiction with European and Brazilian (13) studies, it appears that treatment should be given for more than 7 days in other countries including Iran and USA (10, 11, 14) . The issue of cost further complicates the choice of therapy, especially in underdeveloped countries. The standard therapeutic regimen currently available consists of an association of a proton-pump inhibitor (PPI) and clarithromycin, with either amoxicillin or metronidazole (15, 16) . Increasing resistance to clarithromycin and its decreasing efficacy against H. pylori has prompted the search for alternative therapies. The azilide antibiotic, azithromycin, is a potentially attractive therapeutic agent for H. pylori given its excellent mean inhibitory concentration for this organism as well as its high tissue and mucus penetration, and long biological half-life (17) (18) (19) . However, results from the available published trials utilizing azithromycin are conflicting (20, 21) . The purpose of this study is to investigate the effect of azithromycin based triple therapy in H. pylori eradication in comparison to standard clarithromycin based triple therapy in Iran. Significance was accepted at a P-value of <0.05.
MATERIAL and METHODS

Between
RESULTS
In the per protocol analysis, 63 out of 76 patients in OAC and 67 out of 89 patients in OAA group responded to treatment and were noted to have complete eradication of H. pylori infection (P= 0.158). In the subgroup of patients with peptic ulcer disease, 51 out of 61 patients receiving OAC regimen and 45 out of 61 patients receiving OAA regimen responded to treatment, respectively (P= 0.134). Although 17 (22.3%) in the OAC group and 31 (16.8%) in the OAA group had experienced at least some degree of side effect, only one patient in each group could not complete the courses because of noted severe skin eruptions (Table 2) .
DISCUSSION
Although multiple drugs have been effective in vivo and in vitro against H. pylori, no drug combination to date has been totally effective. In a pooled analysis of anti-H. pylori treatment regimens, clarithromycin based triple regimens with 76%-85% eradication rate have been considered the most effective anti-H. pylori therapeutic strategies (7, 18, 25 In more recent studies, bismuth based quadruple therapy has been best in regards to eradication rate, probably due to the emergence of macrolid resistant strains (25) . Eradication rate in another study has been as low as 35.6% (26) . The most acceptable duration has been determined to be between ten and fourteen days (25, 27) . Although shorter courses of treatment (i.e. one to five days) have demonstrated eradication rates of 89% to 95%, and has increased patient compliance potential (28, 29) . Nevertheless, in the USA and most of the developing countries short course therapy has seen suboptimal results (10, 11, 14) . The azilide antibiotic, azithromycin, is acid stable and has a very good in vitro activity against H. pylori. Azithromycin has an excellent mean inhibitory (MIC) and bactericidal (MBC) concentrations for this organism of 0.25 mg/L and 0.5 mg/L, respectively (17, 30) . The drug bioavailability is greatly reduced when given with food. After oral administration, the drug preferentially concentrates in the tissue rather than plasma (30, 31) . This accounts for the long biological half-life of azithromycin, which is measured in days rather than hours (27, 30, 31) . When comparing to clarythromycin, it is less expensive and more affordable as well. The above mentioned characteristics make azithromycin an attractive choice to include in anti H. pylori regimens. So far multiple trials utilizing azithromycin based regimens with different methods, drug combinations, treatment durations, and with paradoxical results have been conducted (1, 20, 21, (30) (31) (32) (33) (34) (35) (36) . Several studies obtained good efficacy in H. pylori eradication with short-term triple therapy using azithromycin, amoxicillin, and a proton pump inhibitor (33, 37) . In respect to the high biologic half life of azithromycin, several trials have tested azithromycin 500 mg/d for 3 days administered in fasting patients, in combination with a proton pump inhibitor and amoxicillin. The cure rates on an ITT analysis, ranged from 22% to 93% (20, 33, 38, 39) . Higher milligram doses may be more effective (31) . In a Russian study, a seven day course of triple therapy with only three days coverage of azithromycin 1000 mg once daily resulted in 72% ITT eradication (21) . In a randomized control trial in which pan-toprazole, amoxicillin, and either clarithromycin or azithromycin were administered for seven days, eradication rates were 81% and 78% respectively and both regimens were considered to be suboptimal (40) . In a Korean study, seven days course of levofloxacin, azithromycin and omeprazole have not been demonstrated to be more effective than seven days standard triple therapy (41) . The low eradication rates observed in aforementioned studies may be due in part to short duration of azithromycin use, low total azithromycin dose, or variation in antibiotic resistance profile of H. pylori in different geographic areas of the world. To take into account these probabilities, our study utilized azithromycin for an entire ten day course of treatment, and with a higher dosage comparing to previous studies. 
